Trifluridine

Trifluridine has been studied in 2 papers since 2024: 1 observational study in people, 1 in animals; 1 in the past year. The newest paper, Dec 3, 2025: “The crosstalk between ubiquitination and GlcNAcylation of CHAF1A regulates HIV-1 latency and reactivation”.

Intervention

2 papers study it5 findingsUpdated

PubChemChEBI

See all 2 papers on trifluridine

At a glance

The findings reach mice, none yet in people. 2 independent labs in 2 countries; 26 trials, none about aging, 1 with no results posted.

None of its findings points the other way.

Cells and mice: a single group. Worms or flies and humans: nothing yet.
  • 2 independent labs in 2 countries
  • 26 trials, none about aging, 1 with no results posted
  • Funders: Agence Nationale de la Recherche and 8 more
  • Humans1
  • Animals1

What did studies of trifluridine find?

5

Studies of trifluridine measured 5 outcomes, among them CHAF1A, HIV-1 latency and clinical signs of progeria.

CHAF1A

downin human cells1

1 study
  1. Trifluridine decreases CHAF1A in human cells.

    “trifluridine, a Food and Drug Administration-approved antiviral drug, reactivates latent HIV-1 by disrupting O-GlcNAcylation, triggering CHAF1A ubiquitination and proteasomal degradation.”

    Cells

    The crosstalk between ubiquitination and GlcNAcylation of CHAF1A regulates HIV-1 latency and reactivation

    Journal of virology

More on CHAF1A

HIV-1 latency

downin human cells1

1 study
  1. Trifluridine inhibits HIV-1 latency in human cells.

    “We identify trifluridine as a novel LRA capable of disrupting O-GlcNAcylation to degrade CHAF1A, thereby effectively reversing latency in primary cells.”

    Cellsprimary cells

    The crosstalk between ubiquitination and GlcNAcylation of CHAF1A regulates HIV-1 latency and reactivation

    Journal of virology

More on HIV-1 latency

Clinical signs of progeria

downin mice1

1 study
  1. Trifluridine decreases clinical signs of progeria in a mouse model of HGPS.

    “trifluridine treatment in vivo was able to alleviate aortic VSMCs loss and clinical sign of progeria”

    Animalsin a mouse model of HGPS

    Inhibition of poly(ADP-Ribosyl)ation reduced vascular smooth muscle cells loss and improves aortic disease in a mouse model of human accelerated aging syndrome

    Cell death & disease

Aortic VSMC loss

downin mice1

1 study
  1. Trifluridine decreases aortic VSMC loss in a mouse model of HGPS.

    “trifluridine treatment in vivo was able to alleviate aortic VSMCs loss and clinical sign of progeria”

    Animalsin a mouse model of HGPSaorta

    Inhibition of poly(ADP-Ribosyl)ation reduced vascular smooth muscle cells loss and improves aortic disease in a mouse model of human accelerated aging syndrome

    Cell death & disease

NAD+

upin human cells1

1 study
  1. Trifluridine increases NAD+ in human cells (VSMCs differentiated from HGPS patient iPSCs, via decreased PARP-1 activity).

    “we identified a new compound, trifluridine able to increase NAD+ levels through decrease of PARP-1 activity.”

    CellsVSMCs differentiated from HGPS patient iPSCs, via decreased PARP-1 activityvascular smooth muscle cell

    Inhibition of poly(ADP-Ribosyl)ation reduced vascular smooth muscle cells loss and improves aortic disease in a mouse model of human accelerated aging syndrome

    Cell death & disease

More on NAD+

Who is developing trifluridine?

3 companies: EMD Serono Research & Development Institute, AbbVie and Taiho Oncology.

Companies
  • EMD Serono Research & Development InstitutePhase 3metastatic colorectal cancer
  • AbbViePhase 3colorectal cancer
  • Taiho OncologyPhase 3refractory metastatic colorectal cancer

Trial sponsors

Latest

Dec 2025: 1Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months